Skip to content

Growth and Tolerance of Healthy Term Infants to a New Infant Formula

Growth and Tolerance of Healthy Term Infants to a New Infant Formula

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01137877
Enrollment
399
Registered
2010-06-07
Start date
2010-05-31
Completion date
2010-10-31
Last updated
2010-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Term Infants

Brief summary

The objective of this study is to evaluate the effect of two experimental milk-based infant formulas on the growth and gastrointestinal (GI) tolerance of term infants.

Interventions

OTHERMilk based infant formula powder

milk based infant formula ad lib

OTHERInvestigational Infant Formula #1

Milk based infant formula ad lib

OTHERInvestigational Infant Formula #2

Milk based infant formula powder ad lib

OTHERHuman Milk

Human milk ad lib

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Days to 11 Days
Healthy volunteers
Yes

Inclusion criteria

* in good health * singleton full term birth * Birth weight \> 2490 g. * Infant is between 0 and 11 days of age * Infants using medications , home remedies , herbal preparations, prebiotics, probiotics or rehydration fluids that might affect GI tolerance * If formula-fed, parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study * If human milk-fed, parent(s) confirm their intention to feed their infant human milk as the sole source of nutrition * not consuming vitamin or mineral supplements, solid foods or juices through the duration of the study

Exclusion criteria

adverse maternal, fetal or infant medical history with potential for effects on tolerance, growth, and/or development.

Design outcomes

Primary

MeasureTime frame
weight gain14 to 119 days of age

Secondary

MeasureTime frame
GI tolerance14 to 119 days of age
anthropometrics14 to 119 days of age

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026